PCI Pharma Services is investing to expand its flagship manufacturing center in Tredegar, Wales, which will double its highly potent tableting capacity and see an increase in general throughput to support recent and anticipated product launches. It is the latest investment at PCI’s core manufacturing site within its global network, made in direct response to customer needs and market growth.
 
“We are delighted to announce these most recent investments as part of both our business continuity and growth strategies,” said Richard Yarwood, senior vice president, PCI. “This additional capacity will provide greater security to our customers, supporting important clinical programs and new product or market launches.”
 
Since opening its dedicated contained manufacturing facility in 2013, PCI Tredegar has processed more than 60 highly potent products within the unit. The purpose-built, state-of-the-art facility enables PCI to offer a market-leading service; with design for manufacture principles and geometric scale-up delivering seamless development to commercial launch services and speed to market for PCI’s international customer base.
 
Additional investments made at PCI Tredegar since 2013 have further enhanced the facility, complementing the initial build. These include fully contained roller compaction for the processing of molecules sensitive to heat and/or moisture, as well as contained Xcelodose technology delivering drug in capsule solutions for early stage clinical development programs, delivering cost and time efficiencies for customers. In addition to these solid oral dose processing capabilities, further investments in technologies to support the processing of highly potent liquids and semi-solids complete PCI’s full service offering for multiple dosage forms.